Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series

Annals of the Rheumatic Diseases

Volumn 78, Issue 11, 2019, Pages

  Narváez, Javier ^a   Lluch, Judit ^a   Alegre Sancho, Juan José ^b   Molina Molina, Maria ^a   Nolla, Joan Miquel ^a   Castellví, Ivan ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

pulmonary fibrosis; systemic sclerosis; Treatment

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; BACTERIAL INFECTION; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; MIDDLE AGED; MORTALITY RATE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOMYELITIS; POLYARTHRITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCLERODERMA; SYSTEMIC SCLEROSIS; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

EID: 85073480149     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214449     Document Type: Letter

References (6)

1. Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77: 212-20.
2. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010;49: 2408-12.
3. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-Associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study. Ann Rheum Dis 2013;72: 1217-20.
4. Departament de Salut Generalitat de Catalunya, 2018. Dictamen de la Comissió Farmacoterapèutica de la Medicació Hospital ria deDispensació Ambulatòria sobre l'ús de rituximab, tocilizumab Iabatacept per altractament fora d'indicació de l'esclerosi sistèmica refract ria al tractamenthabitual. http://catsalut. gencat. cat/web/. content/minisite/catsalut/proveidors-professionals/medicaments-farmacia/phf-mhda/informes-camse/esclerosi-sistemica/Dictamen-CAMS-ES-web.pdf
5. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192: E3-e19.
6. Khanna D, Jahreis A, Lin CJF. Tocilizumab in systemic sclerosis-Associated interstitial lung disease. Ann Rheum Dis 2019;78: E124.